GlobeNewsWire
25 Sept 2026, 19:35 UTC · 1h ago
Verdict
Headline leans bearish. We score ARDX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH revenue guidance on August 6, 2026.
Priced inannounced August 6, 2026
So whatThe removal of long-term visibility for XPHOZAH likely lowers the terminal value used in DCF models, impacting the stock's valuation multiple.
More negative than 94% of claims this week
A securities class action lawsuit alleges Ardelyx misled investors regarding commercial performance and payer-related access barriers for IBSRELA and XPHOZAH.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inlawsuit filed prior to Sept 25
More negative than 77% of claims this week
The deadline for investors to apply as lead plaintiff in the Ardelyx securities class action is November 16, 2026.
Newpress release dated Sept 25
More negative than 64% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit following a significant stock price drop and the withdrawal of revenue guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
40m ago
−0.9%
Price agrees with the score
$3.42 vs $3.45 close before publication (Sep 24) · not market-adjusted
ARDX chart →
